CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Cash flows from investing activities:
Acquisition, cash acquired	$ 33,583
Supplemental disclosure of non-cash financing activity:
Outstanding convertible debt and accrued interest (in shares)	406,664
Stock valued in conjunction with the acquisition of Surgical Biologics, LLC	7,087,500
Shares issued in conjunction with the acquisition of Surgical Biologics, LLC (in shares)	5,250,000
Beneficial conversion feature value related to the convertible debt issued with regard to the acquisition of Surgical Biologics, LLC	437,500
Beneficial conversion feature related to convertible line of credit	80,000
Beneficial conversion feature value related to convertible debt issued with regard to the Senior Secured Promissory Notes	2,278,052
Beneficial conversion feature related to warrants issued with regard to the Senior Secured Promissory Notes	14,885
Warrants issued in conjunction with Hybrid Debt instruments		141,974
Warrants issued in conjunction with Hybrid Debt instruments (in shares)		500,000
Beneficial conversion feature related to Hybrid Debt instruments		145,474
Amortization of debt discount and deferred financing costs related to the conversion of convertible debt		$ 599,001